Aptus Capital Advisors LLC buys 450 shares of Danaher Co. (NYSE:DHR)

Aptus Capital Advisors LLC increased its position in Danaher Co. (NYSE:DHR – Free Report) by 8.4% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 5,827 shares of the conglomerate’s stock after purchasing an additional 450 shares during the period. Aptus Capital Advisors LLC’s holdings in Danaher were worth $1,456,000 at the end of the most recent quarter.

Other institutional investors have also bought and sold shares of the company. WR Wealth Planners LLC boosted its position in shares of Danaher by 4.4% in the second quarter. WR Wealth Planners LLC now owns 2,438 shares of the conglomerate’s stock valued at $609,000 after purchasing an additional 103 shares in the last quarter. Nilsine Partners LLC boosted its holdings in shares of Danaher by 3.3% in the second quarter. Nilsine Partners LLC now owns 2,013 shares of the conglomerate’s stock worth $503,000 after purchasing an additional 65 shares in the last quarter. nVerses Capital LLC purchased a new stake in shares of Danaher in the second quarter worth about $25,000. Farther Finance Advisors LLC boosted its stake in Danaher by 60.5% in the 2nd quarter. Farther Finance Advisors LLC now owns 7,050 shares of the conglomerate’s stock valued at $1,724,000 after acquiring an additional 2,658 shares in the the last quarter. Finally, Confluence Wealth Services Inc. lifted its position in shares of Danaher by 29.6% during the 2nd quarter. Confluence Wealth Services Inc. now owns 3,374 shares of the conglomerate’s stock valued at $843,000 after acquiring an additional 771 shares during the period. Institutional investors own 79.05% of the company’s shares.

Danaher trading rose 0.9%

Shares of DHR stock opened at $269.31 on Monday. Danaher Co. it has a 52-week low of $182.09 and a 52-week high of $281.70. The company has a 50 day simple moving average of $260.05 and a two hundred day simple moving average of $255.24. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.04, and a current ratio of 1.43. The company has a market cap of $194.50 billion, a price-to-earnings ratio of 45.65, a PEG ratio of 4.43 and a beta of 0.83.

Danaher (NYSE:DHR – Get Free Report ) last issued its earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.57 by $0.15. The company had revenue of $5.74 billion during the quarter, compared to analyst estimates of $5.59 billion. Danaher had a return on equity of 11.06% and a net margin of 16.94%. Danaher’s quarterly revenue was down 2.9% on a year-over-year basis. During the same period last year, the company posted earnings of $2.05 per share. Research analysts anticipate that Danaher Co. will post 7.59 EPS for the current fiscal year.

Analysts on Wall Street are forecasting an increase

A number of research firms have commented on DHR. Stifel Nicolaus upped their target price on shares of Danaher from $235.00 to $250.00 and gave the stock a “hold” rating in a report on Wednesday, July 24th. Leerink Partners upped their price target on Danaher from $275.00 to $280.00 and gave the company an “outperform” rating in a research note on Wednesday, July 24th. Evercore ISI decreased their price target on Danaher from $266.00 to $260.00 and set an “outperform” rating on the stock in a research note on Tuesday, July 2nd. Royal Bank of Canada upped their price objective on Danaher from $297.00 to $300.00 and gave the company an “outperform” rating in a research note on Wednesday, July 24th. Finally, Wells Fargo & Company began coverage on Danaher in a research report on Tuesday, August 27th. They set an “equal weight” rating and a $280.00 price target on the stock. Seven analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. The company presently has a consensus rating of “Moderate Buy” and an average target price of $278.94, according to MarketBeat.com.

See the latest stock report on Danaher

Indoor activity

In related news, SVP Brian W. Ellis sold 9,600 shares of the stock in a transaction dated Thursday, July 25th. The shares were sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the completion of the transaction, the senior vice president now owns 20,230 shares in the company, valued at $5,566,486.80. The transaction was disclosed in a filing with the SEC, which is available via this link. In other news, SVP Georgeann Couchara sold 952 shares of the company’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $268.37, for a total transaction of $255,488.24. Following the transaction, the senior vice president now owns 4,212 shares of the company’s stock, valued at approximately $1,130,374.44. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed via this link. Also, SVP Brian W. Ellis sold 9,600 shares of Danaher stock in a transaction dated Thursday, July 25th. The stock was sold at an average price of $275.16, for a total value of $2,641,536.00. Following the completion of the sale, the senior vice president now directly owns 20,230 shares of the company’s stock, valued at approximately $5,566,486.80. The disclosure for this sale can be found here. Insiders have sold a total of 39,659 shares of company stock worth $11,042,433 over the last ninety days. 11.10% of shares are currently owned by insiders.

Danaher Company Profile

(Free report)

Danaher Corporation designs, manufactures and markets professional, medical, industrial and commercial products and services worldwide. The Biotechnology segments provide bioprocess technologies, consumables and services that advance, accelerate and integrate drug development and manufacturing; cell line and cell culture media development services; cell culture media, process fluids and manufacturing buffers, chromatography resins, filtration technologies, aseptic fill finishing; disposable hardware and supplies and services such as design and installation of complete manufacturing suites; laboratory filtration, separation and purification; laboratory-scale protein purification and analytical tools; reagents, membranes and services; and filtration solutions for health care.

Recommended articles

Get news and reviews for Danaher Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Danaher and related companies with MarketBeat.com’s FREE daily email newsletter.